Chemical states of the N-terminal “lid” of MDM2 regulate p53 binding: Simulations reveal complexities of modulation
暂无分享,去创建一个
Chandra S Verma | Shubhra Ghosh Dastidar | David P Lane | Judith Nicholson | D. Lane | C. Verma | T. Hupp | J. Nicholson | Ted R Hupp | Devanathan Raghunathan | S. G. Dastidar | Devanathan Raghunathan
[1] Matthew P. Jacobson,et al. Conformational Changes in Protein Loops and Helices Induced by Post-Translational Phosphorylation , 2006, PLoS Comput. Biol..
[2] Paul N Barlow,et al. Structure of free MDM2 N-terminal domain reveals conformational adjustments that accompany p53-binding. , 2005, Journal of molecular biology.
[3] J. Turchi,et al. Mdm-2 phosphorylation by DNA-dependent protein kinase prevents interaction with p53. , 1997, Cancer research.
[4] D. Lane,et al. Design of a novel MDM2 binding peptide based on the p53 family , 2009, Cell cycle.
[5] David P. Lane,et al. Design of a synthetic Mdm2-binding mini protein that activates the p53 response in vivo , 1997, Current Biology.
[6] M. Walkinshaw,et al. The effects of phosphomimetic lid mutation on the thermostability of the N-terminal domain of MDM2. , 2010, Journal of molecular biology.
[7] Deepak Srinivasan,et al. Modulation of the p53-MDM2 Interaction by Phosphorylation of Thr18: A Computational Study , 2007, Cell cycle.
[8] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[9] Rafael Brüschweiler,et al. Quantitative lid dynamics of MDM2 reveals differential ligand binding modes of the p53-binding cleft. , 2008, Journal of the American Chemical Society.
[10] T. Shinohara,et al. [In-vivo activation of the p53 pathway by small-molecule antagonists of MDM2]. , 2007, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[11] Chandra S. Verma,et al. Modulation of p53 binding to MDM2: computational studies reveal important roles of Tyr100 , 2009, BMC Bioinformatics.
[12] J. Levine,et al. Surfing the p53 network , 2000, Nature.
[13] A. Levine,et al. Structure of the MDM2 Oncoprotein Bound to the p53 Tumor Suppressor Transactivation Domain , 1996, Science.
[14] Jianpeng Ma,et al. CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..
[15] M. Walkinshaw,et al. Regulation of the E3 ubiquitin ligase activity of MDM2 by an N-terminal pseudo-substrate motif , 2009, Journal of chemical biology.
[16] Alan R. Fersht,et al. Awakening guardian angels: drugging the p53 pathway , 2009, Nature Reviews Cancer.
[17] Shubhra Ghosh Dastidar,et al. Forces mediating protein–protein interactions: a computational study of p53 “approaching” MDM2 , 2010 .
[18] C. Klein,et al. p53--a natural cancer killer: structural insights and therapeutic concepts. , 2006, Angewandte Chemie.
[19] A. Fersht,et al. Binding of p53-derived ligands to MDM2 induces a variety of long range conformational changes. , 2004, Journal of molecular biology.
[20] Shubhra Ghosh Dastidar,et al. Multiple peptide conformations give rise to similar binding affinities: molecular simulations of p53-MDM2. , 2008, Journal of the American Chemical Society.
[21] Deepak Srinivasan,et al. The electrostatic surface of MDM2 modulates the specificity of its interaction with phosphorylated and unphosphorylated p53 peptides , 2008, Cell cycle.
[22] M. McCoy,et al. Flexible lid to the p53-binding domain of human Mdm2: Implications for p53 regulation , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[23] C. Verma,et al. Why an A-loop phospho-mimetic fails to activate PAK1: understanding an inaccessible kinase state by molecular dynamics simulations. , 2010, Structure.
[24] H. Carlson,et al. Computational studies and peptidomimetic design for the human p53–MDM2 complex , 2004, Proteins.